AI Summary
Everyone over 6 months old should get the latest covid-19 booster according to a federal expert panel. The booster could prevent 100,000 more hospitalizations per year. The CDC's Advisory Committee voted in favor of the motion. The FDA has approved the new booster. Only 17% of the population received the last booster, but those who did were less likely to get very sick or die. The virus can cause severe illness in those without underlying conditions, including children. The number of hospitalized covid patients has increased recently. The boosters are made by Moderna and Pfizer/BioNTech.
Everyone over the age of 6 months should get the latest covid-19 booster, a federal expert panel recommended Tuesday after hearing an estimate that universal vaccination could prevent 100,000 more hospitalizations each year than if only the elderly were vaccinated.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted 13-1 for the motion after months of debate about whether to limit its recommendation to high-risk groups. A day earlier, the FDA approved the new booster, stating it was safe and effective at protecting against the covid variants currently circulating in the U.S.
After the last booster was released, in 2022, only 17% of the U.S. population got it — compared with the roughly half of the nation who got the first booster after it became available in fall 2021. Broader uptake was hurt by pandemic weariness and evidence the shots don’t always prevent covid infections. But those who did get the shot were far less likely to get very sick or die, according to data presented at Tuesday’s meeting.
The virus sometimes causes severe illness even in those without underlying conditions, causing more deaths in children than other vaccine-preventable diseases, as chickenpox did before vaccines against those pathogens were universally recommended.
The number of hospitalized patients with covid has ticked up modestly in recent weeks, CDC data shows, and infectious disease experts anticipate a surge in the late fall and winter.
The shots are made by Moderna and by Pfizer and its German partner, BioNTech,